Zacks Small Cap Has Strong Estimate for EVAX FY2024 Earnings

Evaxion Biotech A/S (NASDAQ:EVAX) – Equities researchers at Zacks Small Cap raised their FY2024 earnings per share estimates for shares of Evaxion Biotech A/S in a research note issued on Wednesday, January 15th. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings of ($0.16) per share for the year, up from their previous forecast of ($0.80). The consensus estimate for Evaxion Biotech A/S’s current full-year earnings is ($0.15) per share. Zacks Small Cap also issued estimates for Evaxion Biotech A/S’s Q4 2024 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.14) EPS and FY2025 earnings at ($0.74) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of Evaxion Biotech A/S in a research note on Friday, November 1st.

Evaxion Biotech A/S Trading Up 2.1 %

EVAX stock opened at $3.36 on Friday. The company has a 50 day moving average of $6.37 and a two-hundred day moving average of $11.80. Evaxion Biotech A/S has a 12-month low of $3.17 and a 12-month high of $68.05. The company has a current ratio of 1.00, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.40. The company had revenue of $3.02 million for the quarter, compared to analyst estimates of $0.19 million.

Hedge Funds Weigh In On Evaxion Biotech A/S

A hedge fund recently raised its stake in Evaxion Biotech A/S stock. Armistice Capital LLC grew its holdings in Evaxion Biotech A/S (NASDAQ:EVAX) by 6.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 392,000 shares of the company’s stock after acquiring an additional 25,000 shares during the period. Armistice Capital LLC owned 7.24% of Evaxion Biotech A/S worth $1,137,000 as of its most recent SEC filing. 11.04% of the stock is owned by institutional investors and hedge funds.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.